Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
North American MEA Workshop
The North American MEA Workshop is focused on new in vitro microelectrode array approaches for assessing cardiac and neuro activity. MEA technology is currently being validated within the CiPA initiative to guide future regulatory cardiac safety testing.
At the workshop, leaders in the field will present their experiences on how MEA is being utilized within large Pharma companies and other organizations.
The event is free of charge with refreshments and lunch provided.
View Workshop Details
New York Times reports groundbreaking ALS research supported by Axion’s Maestro
Kevin Eggan, of the Harvard Stem Cell Institute, is recognized in the New York Times for his work advancing treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. Dr. Eggan discovered electrical signaling deficits in human cells derived from ALS patients. Using these cells and a number of screening technologies, including Axion’s Maestro system, he identified a candidate drug slated for testing in ALS patients later this year.
Read NYTimes Article